Privium Fund Management B.V. Krystal Biotech, Inc. Transaction History
Privium Fund Management B.V.
- $401 Million
- Q3 2024
A detailed history of Privium Fund Management B.V. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 6,350 shares of KRYS stock, worth $1.13 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
6,350
Previous 6,420
1.09%
Holding current value
$1.13 Million
Previous $1.18 Million
2.04%
% of portfolio
0.29%
Previous 0.33%
Shares
9 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.4MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$703 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$508 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$467 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$259 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$176 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.57B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...